Wegovy Dosing Schedule and Chart: 0.25 mg to Maintenance

Unlike Ozempic, where the later steps are optional, the Wegovy label schedules the same four steps for every patient, on a 4-week rhythm, before maintenance. The label's Table 1 applies to all approved uses, in adults and in patients aged 12 and older.

The label builds in one adjustment: if a dose is not tolerated during escalation, consider delaying the next step by 4 weeks. The schedule is the shortest route to maintenance, not a deadline. What the 7.2 mg step involves, including its side-effect profile, is covered on the semaglutide max dose page.

The Wegovy maintenance dose depends on what it is prescribed for. The label lists four uses for the injection, each with its own options:

For every use, the label says to weigh treatment response and tolerability when choosing between the options. 1.7 mg is not a failed dose: it is an approved maintenance dose in its own right, and the label's trial data show it working (see the results section below).

Wegovy injection comes in three device types, and the label tells prescribers to train patients on the specific one they receive and retrain if it changes.

Notice the volumes. The 1.7 mg, 2.4 mg and 7.2 mg single-dose pens all hold 0.75 mL, so their concentrations differ (about 2.27, 3.2 and 9.6 mg/mL). On Wegovy a volume tells you nothing about the dose; only the milligram strength on the pen does. The FlexTouch instructions also warn not to set the dose by counting clicks, and the label says FlexTouch is not recommended for self-injection by people with visual impairment.

Compounded semaglutide in vials is a different product, not reviewed by FDA and not equivalent to these devices. If a prescriber has written a dose for one, the volume is units = dose in mg ÷ (vial mg ÷ mL) × 100 on a U-100 syringe. At an EXAMPLE concentration of 2.5 mg/mL only, 1.7 mg is 0.68 mL (68 units) and 2.4 mg is 0.96 mL (96 units). The lower steps are worked through on the Ozempic dosage chart; check your own vial in the semaglutide calculator or mg to mL converter, and read the markings with the syringe measurement guide.

Wegovy tablets (first added to the label in December 2025) are approved for weight reduction and cardiovascular risk reduction in adults, not for adolescents or MASH. The ladder runs in 30-day blocks:

The administration rules are strict because absorption depends on them: one tablet each morning on an empty stomach, swallowed whole with up to 4 ounces of water and no other liquid, then at least 30 minutes before food, drinks or other oral medicines. Never more than one tablet a day. If escalation is not tolerated, the label says to consider delaying it; if 25 mg is not tolerated, to consider switching to Wegovy injection 1.7 mg.

The label gives exact timing in both directions:

• Injection to tablets: patients on Wegovy 2.4 mg injection can switch. Start 25 mg tablets once daily one week after the last 2.4 mg injection.
• Tablets to injection: the day after the last 25 mg tablet, start Wegovy 2.4 mg once weekly. For patients who did not tolerate 25 mg tablets, consider 1.7 mg injection instead.
• Type 2 diabetes on 25 mg tablets needing more weight reduction: consider switching to 1.7 mg injection and then following the injection escalation.

Tablet and injection milligrams are not interchangeable. 25 mg by mouth daily and 2.4 mg by injection weekly are paired on the label because of absorption, not because the numbers are equivalent.

Wegovy's injection rule is framed around the next dose, not the missed one:

The re-escalation row is the one people miss. After two or more skipped weeks, going straight back to 2.4 mg risks the nausea and vomiting the ladder exists to avoid; which lower dose to restart at is for the prescriber. The Medication Guide also allows changing the injection day, as long as the last dose was given 2 or more days before.

Same molecule, same manufacturer, different labels. Ozempic's doses are covered on the Ozempic dosage chart; the table below lines up the parts that differ.

The Wegovy label also states that it should not be used together with other semaglutide-containing products or any other GLP-1 receptor agonist, so the two are alternatives, not add-ons. For the whole class side by side, including tirzepatide and liraglutide, see GLP-1 medications.

The label's own trials put numbers on the 1.7 mg versus 2.4 mg choice. Populations and durations differ between studies, so compare within a row, not across rows.

Gastrointestinal side effects follow the same direction as dose. The full incidence tables, including the 7.2 mg data, are in the semaglutide side effects guide, and the compound reference is on the semaglutide dosage page.